Search results for "HERA"

showing 10 items of 14928 documents

The cyto-protective effects of LH on ovarian reserve and female fertility during exposure to gonadotoxic alkylating agents in an adult mouse model.

2021

Abstract STUDY QUESTION Does LH protect mouse oocytes and female fertility from alkylating chemotherapy? SUMMARY ANSWER LH treatment before and during chemotherapy prevents detrimental effects on follicles and reproductive lifespan. WHAT IS KNOWN ALREADY Chemotherapies can damage the ovary, resulting in premature ovarian failure and reduced fertility in cancer survivors. LH was recently suggested to protect prepubertal mouse follicles from chemotoxic effects of cisplatin treatment. STUDY DESIGN, SIZE, DURATION This experimental study investigated LH effects on primordial follicles exposed to chemotherapy. Seven-week-old CD-1 female mice were randomly allocated to four experimental groups: C…

0301 basic medicineLHAlkylating Agentsfertility preservationmedia_common.quotation_subjectDNA repair LH cancer chemotherapy fertility preservation follicle protection ovoprotectionDNA repairOvaryMice SCIDBiologychemotherapyAndrology03 medical and health sciencesMice0302 clinical medicineOvarian FollicleMice Inbred NODPregnancyFollicular phasemedicineAnimalsHumanscancerFertility preservationOvarian follicleOvarian reserveOvarian ReserveOvulationmedia_commonReproductive Biology030219 obstetrics & reproductive medicineRehabilitationObstetrics and GynecologyOriginal ArticlesOocytemedicine.diseaseAcademicSubjects/MED00905Premature ovarian failure030104 developmental biologymedicine.anatomical_structureReproductive Medicinefollicle protectionovoprotectionlipids (amino acids peptides and proteins)FemaleHuman reproduction (Oxford, England)
researchProduct

A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening

2018

Graphical abstract

0301 basic medicineLK Polo-like kinasePolo-like kinaseCell cycleIC50 50% inhibition concentrationVirtual drug screeningPLK103 medical and health sciences0302 clinical medicineNeoplasmsTargeted chemotherapylcsh:Science (General)MitosisComputingMethodologies_COMPUTERGRAPHICSCDK cyclin-dependent kinasePBD Polo-box domainPyRxNatural productslcsh:R5-920MultidisciplinaryMicroscale thermophoresisKinaseChemistryCell cycleCell biology030104 developmental biology030220 oncology & carcinogenesisCancer cellOriginal ArticleCAMKK2 calcium/calmodulin-dependent protein kinase kinase 2PC Polo-box caplcsh:Medicine (General)Multipolar spindleslcsh:Q1-390Journal of Advanced Research
researchProduct

Risk factors for anthroponotic cutaneous leishmaniasis in unresponsive and responsive patients in a major focus, southeast of Iran

2018

Cutaneous leishmaniasis (CL) is a serious health challenge at the global level due to Leishmania tropica. This study was conducted to evaluate the risk factors associated with anthroponotic CL (ACL) in unresponsive (patient who does not heal and remains with an active lesion, despite receiving two courses of intra-lesional Glucantime along with cryotherapy and one cycle of systemic Glucantime) and responsive patients in a major focus in southeastern Iran. A case-control study was conducted from April 2015 to October 2016 in the southeast of Iran. Patients were recruited in a major ACL focus from unresponsive and responsive cases. These patients were compared for environmental, clinical, and…

0301 basic medicineLeishmania tropicamedicine.medical_treatmentSocial Scienceslcsh:MedicineScarsCryotherapyIranPathology and Laboratory MedicineLogistic regressionPolymerase Chain ReactionGeographical Locations0302 clinical medicineRisk FactorsZoonosesMedicine and Health Scienceslcsh:ScienceLeishmaniasisProtozoansLeishmaniaMultidisciplinaryGeographybiologyEukaryotaInfectious Diseasesmedicine.symptomResearch ArticleNeglected Tropical Diseasesmedicine.medical_specialtyAsiaPatients030106 microbiology030231 tropical medicineLeishmaniasis CutaneousHuman GeographyLesion03 medical and health sciencesSigns and SymptomsCutaneous leishmaniasisDiagnostic MedicineInternal medicineParasitic DiseasesmedicineHumansProtozoan Infectionsbusiness.industrylcsh:ROrganismsHealth Risk AnalysisBiology and Life SciencesOdds ratioDNA ProtozoanTropical Diseasesmedicine.diseasebiology.organism_classificationParasitic ProtozoansConfidence intervalHealth CareAge GroupsLeishmania tropicaCase-Control StudiesPeople and PlacesLesionsEarth SciencesHousingPopulation Groupingslcsh:QbusinessPLOS ONE
researchProduct

Good's syndrome and recurrent leishmaniasis: A case report and review of literature

2020

We report the case of a 56-year-old Caucasian male affected by thymoma and myasthenia gravis that developed recurrent visceral leishmaniasis 11 years after thymectomy. After treatment of each relapse with liposomal amphotericin B the PCR-Leishmania was negative and the patient showed clinical improvement. An immunologic work-up was performed showing lymphopenia with an important decrease in CD4+ T cells (52 cells/μ) and CD4/CD8 ratio (0.2). HIV test was negative. On the basis of previous thymoma and myasthenia gravis and on the basis of the immunological profile a diagnosis of Good's syndrome was made. Since IFNγ plays a main role in the control of Leishmania infection the production of IFN…

0301 basic medicineLeishmaniasiThymomamedicine.medical_treatmentT cellImmunologyLiposomal amphotericin BCase ReportGood's syndromeCD4+ T cell03 medical and health sciences0302 clinical medicinemedicineIntensive care medicinelcsh:Social sciences (General)lcsh:Science (General)LeishmaniasisInternal medicineInfectious diseaseMultidisciplinarybusiness.industryLeishmaniasisImmunotherapymedicine.diseaseLaboratory medicineCD4+ T cellsMyasthenia gravisThymectomy030104 developmental biologyVisceral leishmaniasismedicine.anatomical_structureImmunologylcsh:H1-99business030217 neurology & neurosurgeryCD8IFNγlcsh:Q1-390Heliyon
researchProduct

Opportunities and challenges for drug development: public-private partnerships, adaptive designs and big data

2016

Drug development faces the double challenge of increasing costs and increasing pressure on pricing. To avoid that lack of perceived commercial perspective will leave existing medical needs unmet, pharmaceutical companies and many other stakeholders are discussing ways to improve the efficiency of drug Research and Development. Based on an international symposium organized by the Medical School of the University of Duisburg-Essen (Germany) and held in January 2016, we discuss the opportunities and challenges of three specific areas, i.e., public-private partnerships, adaptive designs and big data. Public-private partnerships come in many different forms with regard to scope, duration and typ…

0301 basic medicineLeverage (finance)Big dataMedizinReviewAppropriate useadaptive trial design03 medical and health sciencesDrug DevelopmentInformed consentinvestigator-initiated studiesbig dataPharmacology (medical)RepurposingPharmacologyInformed Consentbusiness.industryManagement sciencelcsh:RM1-950Public relationsEuphemismpublic-private partnershipPublic–private partnership030104 developmental biologylcsh:Therapeutics. PharmacologyDrug developmentPrivacyBusinesspublic–private partnershipFrontiers in Pharmacology
researchProduct

Deep Brain Stimulation and L-DOPA Therapy: Concepts of Action and Clinical Applications in Parkinson's Disease.

2018

L-DOPA is still the most effective pharmacological therapy for the treatment of motor symptoms in Parkinson's disease (PD) almost four decades after it was first used. Deep brain stimulation (DBS) is a safe and highly effective treatment option in patients with PD. Even though a clear understanding of the mechanisms of both treatment methods is yet to be obtained, the combination of both treatments is the most effective standard evidenced-based therapy to date. Recent studies have demonstrated that DBS is a therapy option even in the early course of the disease, when first complications arise despite a rigorous adjustment of the pharmacological treatment. The unique feature of this therapeu…

0301 basic medicineLevodopaParkinson's diseaseDeep brain stimulationglobus pallidus internus (GPi)medicine.medical_treatmentParkinson's diseaseCentral nervous systemStimulationDiseaseReviewlcsh:RC346-42903 medical and health sciencesTherapeutic approach0302 clinical medicinemedicinelevodopadeep brain stimulation (DBS)lcsh:Neurology. Diseases of the nervous systembusiness.industryDopaminergicmedicine.diseasenervous system diseases030104 developmental biologymedicine.anatomical_structureNeurologyNeurology (clinical)businessNeurosciencesubthalamic nucleus (STN)030217 neurology & neurosurgerymedicine.drugFrontiers in neurology
researchProduct

Medicinal Plants and Natural Products as Potential Sources for Antiparkinson Drugs

2016

Parkinsonʼs disease is a progressive neurodegenerative dysfunction characterized by the loss of pigmented dopaminergic neurons of the nigrostriatal system with a consequent dopamine decrease. The reduction of dopamine levels produces neuronal damage, depigmentation of the substantia nigra, and the presence of intracellular inclusions in dopaminergic neurons. Treatments for Parkinsonʼs disease aim for improving these motor symptoms by increasing the dopaminergic signal in the striatum with levodopa in combination with enzyme inhibitors or anticholinergic drugs. Nevertheless, natural products can act as neuroprotective agents by reducing the progression of the disease and the inflammatory pro…

0301 basic medicineLevodopaPharmaceutical ScienceSubstantia nigraPharmacologyBiologyNeuroprotectionAnalytical ChemistryAntiparkinson Agents03 medical and health sciences0302 clinical medicineDopamineDrug DiscoverymedicineAnimalsHumansPharmacologyBiological ProductsPlants MedicinalPlant ExtractsOrganic ChemistryDopaminergicAntiparkinsonian AgentAntiparkinson drug030104 developmental biologynervous systemComplementary and alternative medicineAntiparkinson AgentsMolecular Medicine030217 neurology & neurosurgeryPhytotherapymedicine.drugPlanta Medica
researchProduct

Pre-dopa Deep Brain Stimulation: Is Early Deep Brain Stimulation Able to Modify the Natural Course of Parkinson’s Disease?

2020

Deep brain stimulation (DBS) is an established therapy for the management of Parkinson's disease (PD). However, DBS is indicated as the disease progresses and motor complications derived from pharmacological therapy arise. Here, we evaluate the potential of DBS prior to levodopa (L-Dopa) in improving quality of life (QoL), challenging the state of the art for DBS therapy. We present data on clinical manifestation, decision finding during early indication to DBS, and trajectories after DBS. We further discuss current paradigms for DBS and hypothesize on possible mechanisms. Six patients, between 50 and 67 years old, presenting at least 5 years of PD symptoms, and without L-Dopa therapy initi…

0301 basic medicineLevodopamedicine.medical_specialtyDeep brain stimulationParkinson's diseasemedicine.medical_treatmentDiseaselcsh:RC321-57103 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationQuality of lifemedicineAdverse effectlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryOriginal Researchsubthalamic nucleusbusiness.industryGeneral Neuroscienceearly deep brain stimulationmedicine.diseasenervous system diseasesdeep brain stimulationClinical trialSubthalamic nucleusearly intervention030104 developmental biologysurgical procedures operativenervous systemParkinson’s diseasebusinesstherapeutics030217 neurology & neurosurgerymedicine.drugNeuroscienceFrontiers in Neuroscience
researchProduct

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation

2021

Sepsis causes high mortality in the setting of septic shock. LEADER and other trials revealed cardioprotective and anti-inflammatory properties of glucagon-like peptide-1 (GLP-1) analogs like liraglutide (Lira). We previously demonstrated improved survival in lipopolysaccharide (LPS)-induced endotoxemia by inhibition of GLP-1 degradation. Here we investigate the effects of Lira in the polymicrobial sepsis model of cecal ligation and puncture (CLP). C57BL/6J mice were intraperitoneally injected with Lira (200 µg/kg/d

0301 basic medicineLipopolysaccharidePhysiologyglucagon-like peptide-1 (GLP-1)Clinical Biochemistryperitoneal and polymicrobial sepsisInflammationRM1-950030204 cardiovascular system & hematologyPharmacologymedicine.disease_causeBiochemistryArticleendothelial dysfunctionSepsis03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineoxidative stressvascular inflammationEndothelial dysfunctionInterleukin 6Molecular Biologyliraglutidebiologybusiness.industrySeptic shockCell Biologybacterial infections and mycosesmedicine.diseasececal ligation and puncture (CLP)Nitric oxide synthase030104 developmental biologychemistrybiology.proteinTherapeutics. Pharmacologymedicine.symptombusinessOxidative stressincretinsAntioxidants
researchProduct

Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients.

2018

Abstract Eighty percent of hepatocellular carcinoma (HCC) cases occur after cirrhosis from various etiologies. The association between diet and cancer is well accepted, but the links with cirrhosis progression and HCC risk have been poorly investigated. However, we hypothesized that diet could be a modifiable preventive factor for HCC. Thus, the aim of our study was to explore the relationships between dietary factors and the risk of HCC in a population of cirrhotic patients. A total of 582 cirrhotic patients were studied: 401 without HCC (controls) and 181 with HCC (cases). These patients were recruited between 2008 and 2012 for the “CiRCE” case-control study conducted in six French univer…

0301 basic medicineLiver CirrhosisMale*Diet/adverse effectsCirrhosisEndocrinology Diabetes and MetabolismGastroenterologyFood groupchemistry.chemical_compound0302 clinical medicineEndocrinologyDiet and cancerRisk FactorsOdds RatioProspective StudiesProspective cohort study*Case-control studyeducation.field_of_studyNutrition and DieteticsLiver NeoplasmsMiddle Aged3. Good healthHepatocellular carcinomaFemale*Feeding Behavior*Hepatocellular carcinomaFranceLiver Neoplasms/etiology/*prevention and controlVitaminmedicine.medical_specialtyCarcinoma Hepatocellular*CirrhosisPopulation030209 endocrinology & metabolism*Diet03 medical and health sciencesHepatocellular/etiology/*prevention and controlInternal medicinemedicineDiabetes MellitusHumanseducationLiver Cirrhosis/complications/*diet therapyAged030109 nutrition & dieteticsbusiness.industryCarcinomaCase-control studyFeeding Behaviormedicine.diseaseDietLogistic ModelschemistryCase-Control StudiesbusinessEnergy Intake[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyNutrition research (New York, N.Y.)
researchProduct